{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:07:52Z","timestamp":1789988872854,"version":"4.0.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.blre.2022.100993","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:28:48Z","timestamp":1659140928000},"page":"100993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma"],"prefix":"10.1016","volume":"57","author":[{"given":"Joseph","family":"Franz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Myrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.blre.2022.100993_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2022.100993_bb0020","series-title":"COVID-19 and multiple myeloma: frequently asked questions","author":"Vincent Rajkumar","year":"2021"},{"issue":"11","key":"10.1016\/j.blre.2022.100993_bb0025","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1634\/theoncologist.2018-0724","article-title":"Patient-reported factors in treatment satisfaction in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"24","author":"Chari","year":"2019","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.blre.2022.100993_bb0030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2022.100993_bb0035","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2019-126015","article-title":"Updated analysis of Bellini, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2022.100993_bb0040","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2022.100993_bb0045","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2022.100993_bb0050","author":"Laubach"},{"issue":"11","key":"10.1016\/j.blre.2022.100993_bb0055","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"JCO."},{"key":"10.1016\/j.blre.2022.100993_bb0060","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","author":"Costa","year":"2021","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.blre.2022.100993_bb0065","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17474086.2020.1804356","article-title":"Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review","volume":"13","author":"Sanchez","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2022.100993_bb0070","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/bloodadvances.2019000539","article-title":"Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide\/dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2022.100993_bb0075","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ejca.2010.12.026","article-title":"Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients","volume":"47","author":"Guglielmelli","year":"2011","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.blre.2022.100993_bb0080","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.blre.2022.100993_bb0085","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.blre.2022.100993_bb0090","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2022.100993_bb0095","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"JCO."},{"issue":"4","key":"10.1016\/j.blre.2022.100993_bb0100","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.15679","article-title":"Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"184","author":"Kumar","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2022.100993_bb0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41408-022-00626-4","article-title":"Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results","volume":"12","author":"Auner","year":"2022","journal-title":"Blood Cancer J"},{"issue":"20","key":"10.1016\/j.blre.2022.100993_bb0110","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood-2016-05-717769","article-title":"Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100993_bb0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjh.15394","article-title":"Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma","volume":"182","author":"Richardson","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2022.100993_bb0120","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41375-021-01433-9","article-title":"Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma","volume":"36","author":"Zanwar","year":"2022","journal-title":"Leukemia."},{"issue":"12","key":"10.1016\/j.blre.2022.100993_bb0125","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2022.100993_bb0130","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10214","key":"10.1016\/j.blre.2022.100993_bb0135","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.blre.2022.100993_bb0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-021-00593-2","article-title":"Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial","volume":"12","author":"Dimopoulos","year":"2022","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.blre.2022.100993_bb0145","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41375-018-0038-8","article-title":"Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"32","author":"Krishnan","year":"2018","journal-title":"Leukemia."},{"issue":"12","key":"10.1016\/j.blre.2022.100993_bb0150","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/ajh.26361","article-title":"A phase I\/ II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202 )","volume":"96","author":"Voorhees","year":"2021","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100993_bb0155","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1182\/blood-2018-99-111823","article-title":"Cyclophosphamide exerts significant immunomodulatory function in myeloma patients treated with pomalidomide and dexamethasone","volume":"132","author":"Croft","year":"2018","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2022.100993_bb0160","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1080\/10428194.2020.1805111","article-title":"A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"61","author":"Van Oekelen","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.blre.2022.100993_bb0165","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2022.100993_bb0170","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2022.100993_bb0175","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2022.100993_bb0180","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood-2019-124991","article-title":"Overall survival of triple class refractory, penta-exposed multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care: a combined analysis of the STORM and mammoth studies","volume":"134","author":"Costa","year":"2019","journal-title":"Blood."},{"issue":"10262","key":"10.1016\/j.blre.2022.100993_bb0185","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.blre.2022.100993_bb0190","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clml.2019.12.013","article-title":"Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"20","author":"Salcedo","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100993_bb0195","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/blood-2021-148759","article-title":"Once weekly oral selinexor, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma","volume":"138","author":"White","year":"2021","journal-title":"Blood."},{"issue":"36","key":"10.1016\/j.blre.2022.100993_bb0200","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"JCO."},{"issue":"9594","key":"10.1016\/j.blre.2022.100993_bb0205","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.blre.2022.100993_bb0210","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3324\/haematol.2017.185991","article-title":"A phase I\/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma","volume":"103","author":"San-Miguel","year":"2018","journal-title":"Haematologica."},{"issue":"7","key":"10.1016\/j.blre.2022.100993_bb0215","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","article-title":"Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients","volume":"115","author":"Gay","year":"2010","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100993_bb0220","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","article-title":"Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure: Thalidomide in MM and renal failure","volume":"73","author":"Tosi","year":"2004","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2022.100993_bb0225","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hon.2485","article-title":"Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma","volume":"36","author":"Morival","year":"2018","journal-title":"Hematol Oncol"},{"issue":"20","key":"10.1016\/j.blre.2022.100993_bb0230","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2017.76.1742","article-title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and renal impairment: results from a phase II trial","volume":"36","author":"Dimopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2022.100993_bb0235","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.14125","article-title":"A pharmacokinetics and safety phase 1\/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis","volume":"174","author":"Gupta","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2022.100993_bb0240","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bjh.17504","article-title":"A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and\/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial","volume":"194","author":"Bergin","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2022.100993_bb0245","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00277-011-1401-2","article-title":"Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment","volume":"91","author":"Party","year":"2012","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.blre.2022.100993_bb0250","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2022.100993_bb0255","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2022.100993_bb0260","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","article-title":"Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients","volume":"115","author":"Gay","year":"2010","journal-title":"Blood."},{"issue":"34","key":"10.1016\/j.blre.2022.100993_bb0265","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 Trial [published correction appears in J Clin Oncol. 2022 Mar 10;40(8):919]","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2022.100993_bb0270","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41416-019-0581-8","article-title":"Ixazomib-thalidomide-dexamethasone for induction therapy followed by ixazomib maintenance treatment in patients with relapsed\/refractory multiple myeloma","volume":"121","author":"Ludwig","year":"2019","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.blre.2022.100993_bb0275","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.blre.2022.100993_bb0280","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1470-2045(20)30680-X","article-title":"Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study","volume":"22","author":"Laubach","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2022.100993_bb0285","series-title":"A Phase IIb Trial of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma Refractory to Previous Lenalidomide-Containing","article-title":"et al","author":"Sanchez","year":"2022"},{"issue":"1","key":"10.1016\/j.blre.2022.100993_bb0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-018-0154-8","article-title":"Combining carfilzomib and panobinostat to treat relapsed\/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study","volume":"9","author":"Kaufman","year":"2019","journal-title":"Blood Cancer J"},{"issue":"23","key":"10.1016\/j.blre.2022.100993_bb0295","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1182\/blood.V126.23.4221.4221","article-title":"A phase I study of ixazomib in combination with panobinostat and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"126","author":"Reu","year":"2015","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.blre.2022.100993_bb0300","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/bloodadvances.2017007427","article-title":"A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma","volume":"1","author":"Chari","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100993_bb0305","author":"Virgil"},{"issue":"5","key":"10.1016\/j.blre.2022.100993_bb0310","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-021-00490-8","article-title":"Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial","volume":"11","author":"Puig","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.blre.2022.100993_bb0315","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/bloodadvances.2018028027","article-title":"Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma","volume":"3","author":"Mark","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2022.100993_bb0320","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0091-6749(99)70175-2","article-title":"Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy","volume":"103","author":"Fost","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.blre.2022.100993_bb0325","first-page":"815","article-title":"Clarithromycin attenuates autophagy in myeloma cells","volume":"37","author":"Nakamura","year":"2010","journal-title":"Int J Oncol"},{"issue":"9","key":"10.1016\/j.blre.2022.100993_bb0330","first-page":"5","article-title":"Clinical implications of the immunomodulatory effects of macrolides","volume":"117","author":"Tamaoki","year":"2004","journal-title":"Am J Med Suppl"},{"issue":"3","key":"10.1016\/j.blre.2022.100993_bb0335","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2249.1996.46752.x","article-title":"Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells","volume":"104","author":"Matsuoka","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.blre.2022.100993_bb0340","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"issue":"Suppl","key":"10.1016\/j.blre.2022.100993_bb0355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.HS9.0000829600.37424.88","article-title":"P07: results from the CC-220-MM-001 dose-expansion phase of iberdomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"6","author":"van de Donk","year":"2022","journal-title":"Hemasphere."},{"key":"10.1016\/j.blre.2022.100993_bb0360","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2022.100993_bb0365","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clml.2021.08.007","article-title":"Effect of t (11;14) abnormality on outcomes of patients with newly diagnosed multiple myeloma in the connect MM registry","volume":"22","author":"Gasparetto","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2022.100993_bb0370","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2019-125871","article-title":"Phase I\/II study evaluating the safety and efficacy of venetoclax in combination with dexamethasone as targeted therapy for patients with t(11;14) relapsed\/refractory multiple myeloma","volume":"134","author":"Kaufman","year":"2019","journal-title":"Blood."},{"issue":"26","key":"10.1016\/j.blre.2022.100993_bb0375","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"issue":"15-suppl","key":"10.1016\/j.blre.2022.100993_bb0380","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2021.39.15_suppl.7502","article-title":"First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed\/refractory (R\/R) CLL and other hematologic malignancies (HMs)","volume":"39","author":"Ailawadhi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100993_bb0385","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.blre.2022.100993_bb0390","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s10637-016-0374-3","article-title":"A first-in-human phase I study to evaluate the MEK1\/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors","volume":"34","author":"Rosen","year":"2016","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.blre.2022.100993_bb0395","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2022.100993_bb0400","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-142600","article-title":"Safety and preliminary efficacy results from a phase II study evaluating combined BRAF and MEK inhibition in relapsed\/refractory multiple myeloma (rrMM) patients with activating BRAF V600E mutations: the GMMG-Birma trial","volume":"136","author":"Raab","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100993_bb0405","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1182\/blood-2021-147400","article-title":"Disease characteristics of multiple myeloma involving BRAF mutations","volume":"138","author":"Mohamed","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100993_bb0410","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"issue":"16_suppl","key":"10.1016\/j.blre.2022.100993_bb0415","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1200\/JCO.2022.40.16_suppl.8055","article-title":"Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm","volume":"40","author":"Kumar","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:25Z","timestamp":1759436905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":79,"alternative-id":["S0268960X22000674"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100993","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100993"}}